Why the study?
Does phosphorylcholine monoclonal immunoglobulin G antibody preserve cardiac function and reduce infarct size in myocardial ischemia-reperfusion injury?
Does phosphorylcholine monoclonal immunoglobulin G antibody preserve cardiac function and reduce infarct size in myocardial ischemia-reperfusion injury?
Answers are grounded in this paper and cite their sources.
Phosphorylcholine monoclonal IgG antibody therapy represents a potential therapeutic approach to mitigate myocardial ischemia-reperfusion injury by attenuating the post-ischemic inflammatory response.
Phosphorylcholine monoclonal immunoglobulin G antibody attenuates the immediate post-ischemic inflammatory response by reducing the proinflammatory chemokine (C-C motif) ligand 2 chemokine and circulating Ly-6Chi monocytes. This subsequently enhances the post-ischemic repair process, resulting in limited adverse cardiac remodeling and preservation of cardiac function. Therefore, phosphorylcholine monoclonal immunoglobulin G antibody therapy may be a valid therapeutic approach against myocardial ischemia-reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Pluijmert et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: